Background
Methods
Radiotherapy
Exercise interventions
Statistical approach
Results
Intervention group A (n = 30) | Control group B (n = 30) |
P-value | |||
---|---|---|---|---|---|
n
| % | n | % | ||
Age (years) | |||||
Mean (SD) | 61.3 +/- 10.1 | 64.1 +/- 10.9 | 0.304 | ||
Gender | |||||
Male | 14 | 46.7 | 19 | 63.3 | 0.195 |
Female | 16 | 53.3 | 11 | 36.7 | |
Karnofsky-index (median, range) | 80 (70–100) | 80 (70–100) | 0.114 | ||
Primary site | |||||
Lung cancer | 12 | 40.0 | 8 | 26.6 | 0.320 |
Breast cancer | 5 | 16.7 | 6 | 20.0 | 0.542 |
Prostate cancer | 5 | 16.7 | 9 | 30.0 | 0.156 |
Melanoma | 1 | 3.3 | 1 | 3.3 | 1.000 |
Renal cancer | 1 | 3.3 | 2 | 6.7 | 0.875 |
Other | 6 | 20.0 | 4 | 13.4 | 0.325 |
Localization metastases | 0.717 | ||||
Thoracic | 17 | 56.7 | 14 | 46.7 | |
Lumbar | 9 | 30.0 | 13 | 43.3 | |
Thoracic and lumbar | 2 | 6.7 | 2 | 6.7 | |
Sacrum | 2 | 6.7 | 1 | 3.3 | |
Number metastases | 0.257 | ||||
Mean (range) | 1.4 (2–4) | 1.7 (1–5) | |||
Solitary | 22 | 73.3 | 18 | 60.0 | |
Multiple | 8 | 26.7 | 12 | 40.0 | |
Type of metastases | 0.781 | ||||
osteoblast | 9 | 30.0 | 10 | 33.3 | 0.956 |
osteolytic | 21 | 70.0 | 20 | 66.7 | 0.935 |
Distant metastases at baseline | |||||
Visceral | 12 | 40.0 | 5 | 16.7 | 0.045 |
brain | 3 | 10.0 | 4 | 13.4 | 0.688 |
lung | 7 | 23.3 | 4 | 13.4 | 0.320 |
tissue | 8 | 26.7 | 6 | 20.0 | 0.542 |
Pathological fractures | 6 | 20.0 | 9 | 30.0 | 0.371 |
Hormonotherapy | 10 | 33.3 | 16 | 53.3 | 0.118 |
Immunotherapy | 7 | 23.3 | 5 | 16.7 | 0.519 |
Chemotherapy | 25 | 83.3 | 20 | 66.7 | 0.136 |
Neurological deficit | 0 | 0.0 | 2 | 6.7 | 0.150 |
Orthopedic corset at baseline | 7 | 23.3 | 5 | 16.7 | 0.519 |
Radiotherapy dose completed (Gy) | |||||
single dose (median, range) | 3 (2–4) | 3 (2–4) | 1.000 | ||
cumulative dose (median, range) | 30 (30–40) | 30 (30–40) | 1.000 |
Group A | Group B | ||||
---|---|---|---|---|---|
n
| % |
n
| % |
P-value | |
Progressive disease | 22 | 73.3 | 27 | 90.0 | 0.095 |
Local bone progression | 0 | 0.0 | 5 | 16.7 | 0.019 |
Systemic bone progression | 8 | 26.7 | 14 | 46.7 | 0.108 |
Intervention group (n = 30) | Control group (n = 30) | |||||
---|---|---|---|---|---|---|
HR | CI 95 % |
P-value | HR | CI 95 % |
P-value | |
Pathological fracture | 1.288 | 0.371–4.467 | 0.690 | 0.833 | 0.343–2.020 | 0.686 |
KPS | 0.527 | 0.216–1.289 | 0.161 | 0.872 | 0.372–2.043 | 0.752 |
Localization | 0.588 | 0.209–1.655 | 0.315 | 1.166 | 0.504–2.694 | 0.720 |
Number of metastases | 0.602 | 0.200–1.812 | 0.366 | 1.052 | 0.469–2.360 | 0.902 |
Breast cancer | 0.230 | 0.028–1.923 | 0.175 | 0.103 | 0.024–0.442 | 0.002 |
NSCLC | 2.442 | 0.834–7.145 | 0.103 | 0.968 | 0.346–2.712 | 0.951 |
Prostate cancer | 0.950 | 0.237–3.804 | 0.942 | 0.160 | 0.050–0.511 | 0.002 |
Cerebral metastases | 1.529 | 0.409–5.716 | 0.528 | 3.211 | 1.063 − 9.695 | 0.038 |